Processing

Please wait...

Settings

Settings

Goto Application

1. WO2022000708 - USE OF PHOSPHODIESTERASE 4 INHIBITOR ZL-N-91 IN PREPARATION OF ANTI-OSTEOSARCOMA MEDICAMENT

Publication Number WO/2022/000708
Publication Date 06.01.2022
International Application No. PCT/CN2020/108212
International Filing Date 10.08.2020
IPC
A61K 31/341 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
34having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
341not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 35/04 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
04specific for metastasis
Applicants
  • 广州华真医药科技有限公司 GUANGZHOU HUAZHEN PHARMACEUTICAL CO., LTD. [CN]/[CN]
Inventors
  • 赵子建 ZHAO, Allan Zijian
  • 李芳红 LI, Fanghong
  • 许丽君 XU, Lijun
  • 周素瑾 ZHOU, Sujin
  • 赵正刚 ZHAO, Zhenggang
  • 张馨丹 ZHANG, Xindan
Agents
  • 北京三聚阳光知识产权代理有限公司 SUNSHINE INTELLECTUAL PROPERTY INTERNATIONAL CO., LTD.
Priority Data
202010627545.001.07.2020CN
Publication Language Chinese (zh)
Filing Language Chinese (ZH)
Designated States
Title
(EN) USE OF PHOSPHODIESTERASE 4 INHIBITOR ZL-N-91 IN PREPARATION OF ANTI-OSTEOSARCOMA MEDICAMENT
(FR) UTILISATION D'UN INHIBITEUR DE PHOSPHODIESTÉRASE, 4 ZL-N-91, DANS LA PRÉPARATION D'UN MÉDICAMENT ANTI-OSTÉOSARCOME
(ZH) 磷酸二酯酶4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用
Abstract
(EN) Use of PDE4 inhibitor ZL-n-91 in the preparation of an anti-osteosarcoma medicament. The selective PDE4 inhibitor ZL-n-91 has an inhibitory strength for PDE4B and PDE4D of more than 5000 times that of other PDE family members, has strong specificity and less side effects such as vomiting. Experimental results of in vitro cytology show that ZL-n-91 can significantly inhibit the proliferation of osteosarcoma cells, and has a good development and application prospect.
(FR) Utilisation de l'inhibiteur de PDE4, ZL-n-91, dans la préparation d'un médicament anti-ostéosarcome. L'inhibiteur sélectif de PDE4, ZL-n -91, présente une résistance inhibitrice pour PDE4B et PDE4D supérieure à 5 000 fois celle d'autres membres de la famille PDE, présente une forte spécificité et moins d'effets secondaires tels que les vomissements. Les résultats expérimentaux de la cytologie in vitro montrent que ZL-n-91 peut inhiber de manière considérable la prolifération de cellules d'ostéosarcome, et présente une bonne perspective de développement et d'application.
(ZH) PDE4抑制剂ZL-n-91在制备抗骨肉瘤药物中的应用。选择性PDE4抑制剂ZL-n-91对PDE4B和PDE4D的抑制强度是其他PDE家族成员的5000倍以上,特异性强且呕吐等副作用小;体外细胞学实验结果显示ZL-n-91可以显著抑制骨肉瘤细胞的增殖,具有良好的开发应用前景。
Related patent documents
Latest bibliographic data on file with the International Bureau